Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:HROW NASDAQ:MLTX NASDAQ:PRLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$29.98-0.6%$31.32$16.10▼$35.83$1.40B1.29504,141 shs818,430 shsHROWHarrow$39.32+5.0%$39.42$28.54▼$54.85$1.40B0.26602,144 shs569,600 shsMLTXMoonLake Immunotherapeutics$18.71-5.9%$19.08$5.95▼$62.75$1.46B1.041.09 million shs1.05 million shsPRLDPrelude Therapeutics$4.64+19.3%$4.31$0.75▼$5.69$309.82M0.95307,805 shs1.86 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-0.60%+6.09%-11.82%-0.23%+43.24%HROWHarrow+4.97%-10.04%-6.54%-2.29%+12.79%MLTXMoonLake Immunotherapeutics-5.89%-6.73%-5.98%+16.14%-65.65%PRLDPrelude Therapeutics+19.28%+14.85%+5.94%+8.67%+444.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$29.98-0.6%$31.32$16.10▼$35.83$1.40B1.29504,141 shs818,430 shsHROWHarrow$39.32+5.0%$39.42$28.54▼$54.85$1.40B0.26602,144 shs569,600 shsMLTXMoonLake Immunotherapeutics$18.71-5.9%$19.08$5.95▼$62.75$1.46B1.041.09 million shs1.05 million shsPRLDPrelude Therapeutics$4.64+19.3%$4.31$0.75▼$5.69$309.82M0.95307,805 shs1.86 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-0.60%+6.09%-11.82%-0.23%+43.24%HROWHarrow+4.97%-10.04%-6.54%-2.29%+12.79%MLTXMoonLake Immunotherapeutics-5.89%-6.73%-5.98%+16.14%-65.65%PRLDPrelude Therapeutics+19.28%+14.85%+5.94%+8.67%+444.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 2.78Moderate Buy$44.8349.54% UpsideHROWHarrow 2.64Moderate Buy$69.4376.57% UpsideMLTXMoonLake Immunotherapeutics 2.41Hold$24.2129.42% UpsidePRLDPrelude Therapeutics 2.40Hold$7.6765.23% UpsideCurrent Analyst Ratings BreakdownLatest PRLD, MLTX, AVBP, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.007/20/2026HROWHarrow Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/20/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.007/17/2026AVBPArriVent BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026PRLDPrelude Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/1/2026MLTXMoonLake Immunotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $29.006/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/29/2026AVBPArriVent BioPharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$43.00 ➝ $45.005/22/2026AVBPArriVent BioPharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.00(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.44 per shareN/AHROWHarrow$272.30M5.38$0.91 per share43.34$1.41 per share27.89MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/APRLDPrelude Therapeutics$12.14M30.44N/AN/A$1.09 per share4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$166.31M-$3.47N/AN/AN/AN/A-48.98%-45.44%8/14/2026 (Estimated)HROWHarrow-$5.14M-$0.41N/A17.48N/A-5.57%19.59%2.26%8/10/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)PRLDPrelude Therapeutics-$99.50M-$1.00N/AN/AN/AN/A-118.24%-66.12%8/13/2026 (Estimated)Latest PRLD, MLTX, AVBP, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026AVBPArriVent BioPharma-$0.98N/AN/AN/AN/AN/A8/13/2026Q2 2026PRLDPrelude Therapeutics-$0.17N/AN/AN/A$4.78 millionN/A8/10/2026Q2 2026HROWHarrow-$0.23N/AN/AN/A$70.35 millionN/A8/4/2026Q2 2026MLTXMoonLake Immunotherapeutics-$0.90N/AN/AN/AN/AN/A5/12/2026Q1 2026PRLDPrelude Therapeutics-$0.27-$0.13+$0.14-$0.13$4.58 million$4.58 million5/11/2026Q1 2026AVBPArriVent BioPharma-$0.88-$0.96-$0.08-$0.96N/AN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A13.9513.95HROWHarrow10.302.482.30MLTXMoonLake Immunotherapeutics0.398.608.60PRLDPrelude TherapeuticsN/A2.032.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%HROWHarrow72.76%MLTXMoonLake Immunotherapeutics93.85%PRLDPrelude Therapeutics79.72%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma8.58%HROWHarrow12.80%MLTXMoonLake Immunotherapeutics10.40%PRLDPrelude Therapeutics49.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4046.58 million42.58 millionN/AHROWHarrow18037.28 million32.50 millionOptionableMLTXMoonLake Immunotherapeutics273.61 million65.96 millionOptionablePRLDPrelude Therapeutics12079.64 million40.46 millionOptionablePRLD, MLTX, AVBP, and HROW HeadlinesRecent News About These CompaniesEcoR1 Capital LLC Makes New $3.24 Million Investment in Prelude Therapeutics Incorporated $PRLDJuly 28 at 4:07 AM | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Stock Rating Upgraded by Wall Street ZenJuly 25, 2026 | americanbankingnews.comPrelude Therapeutics (NASDAQ:PRLD) Upgraded to "Buy" at Wall Street ZenJuly 25, 2026 | marketbeat.comHC Wainwright Issues Positive Estimate for PRLD EarningsJuly 19, 2026 | americanbankingnews.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Rating of "Hold" by BrokeragesJuly 18, 2026 | marketbeat.comPrelude Therapeutics (PRLD) Upgraded to Buy: Here's WhyJuly 17, 2026 | zacks.comResearch Analysts Offer Predictions for PRLD Q2 EarningsJuly 17, 2026 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Trading Down 1.1% - What's Next?July 14, 2026 | marketbeat.comPrelude TherapeuticsJuly 14, 2026 | fool.comPrelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comEarnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 16, 2026 | finance.yahoo.comPrelude Therapeutics (PRLD) price target increased by 11.49% to 7.01May 14, 2026 | msn.comPrelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline UpdateMay 12, 2026 | quiverquant.comQPrelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 12, 2026 | globenewswire.comWall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a BetMay 8, 2026 | zacks.comD Boral Capital initiates coverage of Prelude Therapeutics (PRLD) with buy recommendationMay 5, 2026 | msn.comPrelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast CancerMay 1, 2026 | uk.finance.yahoo.com9 Best Biotech Penny Stocks to Buy in 2026April 30, 2026 | insidermonkey.comPrelude Therapeutics (PRLD) price target increased by 19.35% to 6.29April 29, 2026 | msn.comPrelude Therapeutics director David P. Bonita acquires $12.5 million in stockApril 24, 2026 | investing.comInsider Buying: Prelude Therapeutics (NASDAQ:PRLD) Director Acquires 2,815,315 Shares of StockApril 24, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRLD, MLTX, AVBP, and HROW Company DescriptionsArriVent BioPharma NASDAQ:AVBP$29.98 -0.18 (-0.60%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$29.98 0.00 (-0.02%) As of 07/28/2026 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Harrow NASDAQ:HROW$39.32 +1.86 (+4.97%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$38.84 -0.48 (-1.22%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.MoonLake Immunotherapeutics NASDAQ:MLTX$18.71 -1.17 (-5.89%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$19.20 +0.49 (+2.62%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Prelude Therapeutics NASDAQ:PRLD$4.64 +0.75 (+19.28%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$4.71 +0.07 (+1.51%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
